ACE2 作为新型冠状病毒（nCoV-2019）管理的潜在靶点。
ACE2 as a Potential Target for Management of Novel Coronavirus (nCoV- 2019).
机构信息
Naft hospital, Tehran, Iran.
Department of Systems Engineering, École de technologie supérieure (ÉTS), Université du Québec, Montreal, QC,, Canada.
出版信息
Curr Drug Discov Technol. 2021;18(6):e130921189567. doi: 10.2174/1570163817999201228215911.
A novel coronavirus termed nCoV-2019 that caused an epidemic of acute respiratory syndrome in humans was first detected in Wuhan, China, in December 2019. nCoV-2019 resulted in thousands of cases of lethal disease all around the world. Unfortunately, there is no specific treatment yet, so a better understanding of the pathobiology of the disease can be helpful. The renin-angiotensin system and its products have several important physiological actions. On the other hand, this system is involved in the pathogenesis of various diseases. In this context, this review article will briefly discuss insights for understanding the role of the angiotensin-converting enzyme 2 (ACE2) receptor as a potentially attractive target for the nCoV-2019-induced acute respiratory syndrome.
一种新型冠状病毒 nCoV-2019 于 2019 年 12 月在中国武汉首次被发现，该病毒可导致人类急性呼吸道综合征疫情。nCoV-2019 已导致全球数千例致命疾病。不幸的是，目前尚无特效治疗方法，因此更好地了解疾病的病理生物学可能会有所帮助。肾素-血管紧张素系统及其产物具有多种重要的生理作用。另一方面，该系统也参与了多种疾病的发病机制。在此背景下，本文将简要探讨理解血管紧张素转换酶 2（ACE2）受体作用的一些新见解，该受体可能是针对 nCoV-2019 引起的急性呼吸综合征的一个有吸引力的潜在靶点。
Zotero 插件